Document:

EX-10.1

 Exhibit 10.1 

INTERNATIONAL STEM CELL CORPORATION 

PROMISSORY NOTE 
 FOR VALUE
RECEIVED, and subject to the terms and conditions set forth herein, on this 8th day of January, 2016 (the “Issuance Date”), International Stem Cell Corporation, a Delaware
corporation (the “Borrower”), hereby unconditionally promises to pay to the order of Andrey Semechkin or his assigns (the “Noteholder”), the principal amount of three million eight hundred ten thousand
dollars ($3,810,000) (the “Loan”), together with all accrued interest thereon, as provided in this Promissory Note (the “Note”). 

1. Previous Loan. On December 10, 2015 Noteholder was issued a Promissory Note in the principal amount of $3,110,000 by the
Borrower (the “Original Note”). The Noteholder and the Borrower have agreed to revise the Original Note to extend the maturity date set forth therein to March 10, 2016. On January 8, 2016, the Noteholder provided an
additional $700,000 of funds to the Borrower and surrendered the Original Note, in return for which the Noteholder was issued this Note, reflecting the revised terms of the Loan. 

2. Final Payment Date; Optional Prepayments. 

2.1 Final Payment Date. The aggregate unpaid principal amount of the Loan and all accrued and unpaid interest shall be due and
payable March 10, 2016 (the “Maturity Date”). 
 2.2 Optional Prepayment. The Borrower may prepay the
Loan in whole or in part at any time or from time to time without penalty or premium by paying the principal amount to be prepaid together with accrued interest thereon to the date of prepayment. No prepaid amount may be reborrowed. 

3. Interest. 

3.1 Interest Rate. The outstanding principal amount of the Loan made hereunder shall bear interest at the annual rate of
One-Half of One Percent (0.50%) from the date the Loan was made until the Loan is paid in full, whether at maturity, by prepayment or otherwise. 

3.2 Interest Payment Dates. Interest shall be payable on maturity, or earlier with respect to any prepayment. 

3.3 Computation of Interest. All computations of interest shall be made on the basis of a year of 360 days and the actual
number of days elapsed. Interest shall accrue on the Loan on the day on which such Loan is made, and shall not accrue on the Loan (or any portion thereof) for the day on which it is paid. 

3.4 Interest Rate Limitation. If at any time and for any reason whatsoever, the interest rate payable on the Loan shall exceed
the maximum rate of interest permitted to be charged by the Noteholder to the Borrower under applicable law, such interest rate shall be reduced automatically to the maximum rate of interest permitted to be charged under applicable law, and that
portion of any sum paid attributable to that portion of such interest rate that exceeds the 

 
maximum rate of interest permitted by applicable law shall be deemed a voluntary prepayment of principal. 

4. Payment Mechanics. All payments of principal and interest shall be made in lawful money of the United States of America by check or
by wire transfer of immediately available funds to the Noteholder’s account at a bank specified by the Noteholder in writing to the Borrower from time to time. 

5. Governing Law. This Note and any claim, controversy, dispute or cause of action based upon, arising out of or relating to this Note,
and the transactions contemplated hereby, shall be governed by the laws of the State of California. 
 IN WITNESS WHEREOF,
the Borrower has executed this Note as of the Issuance Date written above. 
  

					
	BORROWER	 		  	NOTEHOLDER
	International Stem Cell Corporation	 		  	Andrey Semechkin
			
	  
	 		  	  

	 Signature
	 		  	 Signature

			
	 Mahnaz Ebrahimi
	 		  	
	 Chief Financial OfficerEX-10.2

 Exhibit 10.2 

NOTE CONVERSION AGREEMENT 

THIS NOTE CONVERSION AGREEMENT (this “Agreement”) is made as of January 8, 2016, by and among
International Stem Cell Corporation, a Delaware corporation (the “Company”), and Andrey Semechkin (the “Holder”). 

RECITALS 
 A.
Holder is the Co-Chairman and Chief Executive Officer of the Company, and fully understands the present condition, opportunities and risks of the Company, as well as the terms of the contemplated Offering (as defined below). 

B. The Company previously issued that certain promissory note to the Holder on January 8, 2016 and in the principal
amount set forth opposite the Holder’s name on Exhibit A (the “Note”). 
 C. The Company
has proposed and the Holder has agreed to convert the outstanding principal amount of, and all accrued and unpaid interest under (collectively, the “Outstanding Amount”), the Note into shares of the Company’s common
stock (the “Common Stock”), Series A warrants to purchase shares of Common Stock and Series B warrants to purchase shares of Common Stock (collectively, the “Warrants”) on the terms and conditions
equivalent to those offered to purchasers under the Company’s proposed offering set forth on the Registration Statement on Form S-1 (No. 333-205193) (the “Offering”). 

D. The Company and the Holder desire to enter into this Agreement to confirm their agreement to convert all outstanding
principal and interest payable under the Note into shares of the Common Stock and Warrants (the “Conversion”), with such conversion to be effective at the closing of the Offering. 

AGREEMENT 
 In
consideration of the foregoing and the mutual covenants contained herein, the parties hereto agree as follows: 
 1.
Effective at the time of the closing of the Offering, (i) the outstanding principal amount and all accrued and unpaid interest on the Note shall be converted into that number of shares of Common Stock and Warrants which would be issued if
Holder paid such Outstanding Amount in connection with the Offering. Any portion of the Outstanding Amount that would otherwise result in the issuance of a fractional share or fractional warrants shall be repaid in cash. Upon issuance of the shares
of Common Stock and Warrants to the Holder pursuant to this Agreement and payment of the remaining Outstanding Amount (in lieu of fractional shares or warrants), all obligations of the Company to the Holder pursuant to the Note shall immediately
terminate and the Note shall be canceled and have no further force and effect. 
 2. Immediately following the Conversion,
the Holder shall deliver Holder’s Note to the Company for cancellation and the Company shall issue and deliver to the Holder the shares of Common Stock and Warrants (and cash in lieu of fractional shares or warrants) that such Holder is
entitled to receive pursuant to the terms of this Agreement. Notwithstanding the 

 
foregoing or anything to the contrary contained herein, the full amount of the Note shall automatically convert as described herein at the closing of the Offering, without any further action
required by the Holder of the Note, with the delivery of the Note for cancellation being only a matter of administrative maintenance. 

3. Holder understands that the securities received upon conversion of the Note have not been registered under federal or state
securities laws and, as such, cannot be sold unless so registered or an exemption from such registration becomes available in the future. In recognition of the fact that the shares and warrants received upon conversion of the Note will be
“restricted securities,” concurrent with the execution of this Agreement the Company and the Holder will enter into a registration rights agreement (the “Registration Rights Agreement”) in the form attached hereto
as Exhibit B. 
 4. This Agreement (including the Registration Rights Agreement) sets forth the entire agreement
of the parties hereto with respect to the subject matter hereof. 
 5. This Agreement shall be governed by, and construed
and enforced in accordance with, the laws of the State of California. 
 6. This Agreement may be executed electronically
and in counterparts by the parties hereto, all of which together shall constitute one instrument. 
 [THE REMAINDER OF THIS PAGE IS
INTENTIONALLY LEFT BLANK] 

  
 -2- 

 IN WITNESS WHEREOF, the undersigned have executed this Note Conversion Agreement
as of the date first written above. 
  

			
	 COMPANY:

	
	 INTERNATIONAL STEM CELL CORPORATION

		
	 By:
	 	 /s/ Mahnaz Ebrahimi

	 Name:
	 	 Mahnaz Ebrahimi

	 Title:
	 	 CFO

	
	 HOLDER:

	
	 /s/ Andrey Semechkin

	 Andrey Semechkin

 EXHIBIT A 
  

									
	 Holder
	  	Principal Amount	 	  	Accrued Interest*	 
	 Andrey Semechkin
	  	$	3,810,000.00	  	  	$	8,824	  
		  	$	3,810,000.00	  	  	$	8,824	  

  

	*	 through the date of this Note Conversion Agreement 

  
 -4-EX-10.3

 Exhibit 10.3 

REGISTRATION RIGHTS AGREEMENT 

This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 8, 2016,
between International Stem Cell Corporation, a Delaware corporation (the “Company”), and Andrey Semechkin (the “Purchaser”). 

This Agreement is made pursuant to the Note Conversion Agreement, dated as of the date hereof, between the Company and the
Purchaser (the “Conversion Agreement”). 
 The Company and the Purchaser hereby agrees as follows: 

1. Definitions. 

Capitalized terms used and not otherwise defined herein that are defined in the Conversion Agreement shall have the meanings
given such terms in the Conversion Agreement. As used in this Agreement, the following terms shall have the following meanings: 

“Effectiveness Period” shall have the meaning set forth in Section 2. 

“Holder” or “Holders” means the holder or holders, as the case may be, from
time to time of Registrable Securities. 
 “Prospectus” means the prospectus included in a
Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the Commission
pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and
supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus. 

“Registrable Securities” means, as of any date of determination, (a) all shares of Common
Stock issued to Purchaser pursuant to the Conversion Agreement, (b) all shares of Common Stock underlying the Warrants issued to Purchaser pursuant to the Conversion Agreement, and (c) all shares of Common Stock, previously issued or
issuable upon conversion of shares of Preferred Stock or exercise of warrants outstanding as of the date hereof, held by Purchaser, Purchaser’s affiliates or any member of Purchaser’s immediate family (in each case, including any
securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing); provided, however, that any such Registrable Securities shall cease to be
Registrable Securities (and the Company shall not be required to maintain the effectiveness of any, or file another, Registration Statement hereunder with 

 
respect thereto) for so long as (a) a Registration Statement with respect to the sale of such Registrable Securities is declared effective by the Commission under the Securities Act and such
Registrable Securities have been disposed of by the Holder in accordance with such effective Registration Statement, (b) such Registrable Securities have been previously sold in accordance with Rule 144, or (c) such securities become
eligible for resale without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144, as reasonably determined by the Company, upon the advice of counsel to the Company. 

“Registration Statement” means any registration statement required to be filed hereunder
pursuant to Section 2, including the Prospectus, amendments and supplements to any such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or
deemed to be incorporated by reference in any such registration statement. 
 “Rule 415”
means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule. 
 “Rule 424” means Rule 424 promulgated by the Commission pursuant
to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule. 

2. Shelf Registration. On the request of Holder and on one occasion, but only at such time as the Company meets the
requirements for the registration of securities on Form S-3 (or such other registration statement allowing for an offering to be made on a continuous basis pursuant to Rule 415 and providing for the incorporation by reference (similar to Form S-3) of future filings pursuant to the Securities Exchange Act of 1934, as amended), the Company shall prepare and file with the Commission a Registration Statement covering the resale of all (or any requested
portion) of the Registrable Securities by the holders thereof. Subject to the terms of this Agreement, the Company shall use its commercially reasonable efforts to cause a Registration Statement filed under this Agreement to be declared effective
under the Securities Act as promptly as possible after the filing thereof, and shall use its commercially reasonable efforts to keep such Registration Statement continuously effective under the Securities Act until all Registrable Securities covered
by such Registration Statement (i) have been sold, thereunder or pursuant to Rule 144, or (ii) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance
with the current public information requirement under Rule 144 (the “Effectiveness Period”). 

  
 2 

 3. Registration Procedures. 

In connection with the Company’s registration obligations hereunder, the Company shall: 

(a) (i) Prepare and file with the Commission such amendments, including post-effective amendments, to a
Registration Statement and the Prospectus used in connection therewith as may be necessary to keep the Registration Statement continuously effective as to the applicable Registrable Securities for the Effectiveness Period, (ii) cause the
related Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant to Rule 424, (iii) respond as promptly as reasonably
possible to any comments received from the Commission with respect to a Registration Statement or any amendment thereto, and (iv) comply in all material respects with the applicable provisions of the Securities Act and the Exchange Act with
respect to the disposition of all Registrable Securities covered by a Registration Statement during the applicable period in accordance (subject to the terms of this Agreement) with the intended methods of disposition by the Holders thereof set
forth in such Registration Statement as so amended or in such Prospectus as so supplemented. 
 (b) Use its
commercially reasonable efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption
from qualification) of any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable time. 

(c) Comply with all applicable rules and regulations of the Commission. 

4. Registration Expenses. All fees and expenses incident to the performance of or compliance with, this Agreement by
the Company shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. 

5. Miscellaneous. 

(a) Compliance. Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the
Securities Act as applicable to it (unless an exemption therefrom is available) in connection with sales of Registrable Securities pursuant to a Registration Statement. 

(b) Amendments and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be
amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed by the Company and the Holders of a majority of the

  
 3 

 
then outstanding Registrable Securities (for purposes of clarification, this includes any Registrable Securities issuable upon exercise or conversion of any Security). 

(c) Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and
permitted assigns of each of the parties and shall inure to the benefit of each Holder. 
 (d) Execution and
Counterparts. This Agreement may be executed in counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other
party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid
and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof. 

(e) Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this
Agreement shall be determined in accordance with the laws of the State of California. 
 (f) Cumulative Remedies. The
remedies provided herein are cumulative and not exclusive of any other remedies provided by law. 
 (g) Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same
result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without
including any of such that may be hereafter declared invalid, illegal, void or unenforceable. 

  
 4 

 (h) Headings. The headings in this Agreement are for convenience only, do
not constitute a part of the Agreement and shall not be deemed to limit or affect any of the provisions hereof. 
 IN
WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above. 
  

			
	 INTERNATIONAL STEM CELL CORPORATION

		
	 By:
	 	 /s/ Mahnaz Ebrahimi

	 Name:
	 	 Mahnaz Ebrahimi

	 Title:
	 	 CFO

	
	 ANDREY SEMECHKIN

		 	
	 /s/ Andrey Semechkin

	 Andrey Semechkin

  
 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]